



Imperial College Healthcare NHS Trust and CSL Collaborative Working Executive Summary

Project title	Imperial College Healthcare NHS Trust (ICHT) Specialist IgA nephropathy (IgAN) Clinic Collaborative Working Project
Brief Project Summary	This 15-month project will see provision of 0.4 of a full-time equivalent Specialist Nephrology Pharmacist to create and implement a dedicated consultant-led pharmacist-delivered specialist IgA nephropathy (IgAN) clinic at Hammersmith Hospital that will: • Centralise care for both incident and prevalent patients • Enable consistent application of evidence-based treatment protocols • Support safe initiation and monitoring of licensed therapies • Create a platform for education, research, and real-world evidence generation • Build a business case to evidence impact of the service and ensure project continues beyond pilot phase The proposed clinical model is outlined below: • Weekly specialist IgA clinic • All incident cases following central biopsy review • Proactive identification of prevalent patients via biopsy database screening • Consultant-led service, delivered with GN Research SpR support • Co-recruitment to the National Registry of Rare Kidney Diseases (RaDaR), local biobanking, and outcomes databases • Governance readiness: approved by renal senior management team (SMT) at ICHT; treatment protocols and patient materials in place and approved by Local Glomerulonephritis Operations and Pharmacy Groups.

Project objectives	Patients: - To provide consistent, standardised medicines education and support to patients with IgA nephropathy, in line with nationally accepted clinical guidance and locally approved care pathways. - Support shared decision making, including medication review. - Improve equity of access to specialised clinic service NHS: - Increased efficiency for clinicians and the Trust by creating standardised, auditable pathways that support equitable access across North West London - Reduced administrative load on clinicians - Support commissioning and affordability by aligning with NHS England high-cost drug processes and Blueteq prior approval where applicable - Undertake a health economic analysis of the clinic and outcomes (eg consultant vs pharmacy clinic, healthcare utilisation (admissions), requirement of dialysis and transplantation) to support future commissioning of service model and long-term sustainability in a model that delivers improved patient adherence and experience Industry: - Real world evidence generation on clinical effectiveness and safety of this clinical model - Timely access to medications in line with NICE TA implementation - Enhanced experience of partnering with NHS organisations
Roles and responsibilities	Consultant Nephrologist, Imperial College Healthcare NHS Trust Head of Market Access, Value & Pricing UK and Ireland to oversee project delivery for CSL
Financial Contributions	Project Support: CSL Vifor financial contribution £35,867 ICHT indirect contribution £36,400
Plans for publication	A project summary report will be published on the CSL website within 6 months of project completion
Project period	May 2026 – Aug 2027
References	1. KDIGO IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and

	Immunoglobulin A Vasculitis (IgAV). <i>Kidney Int.</i> 2025 Oct;108(4S):S1-S71.
--	---